MS4A1 and B-cell non-Hodgkin lymphoma: Of particular interest is the study reported by Cheng Q, Tan J, and Liu R (95), confirming the effective use of CAR-T cells targeting the CD20 in patients with r/r B-cell NHL treated with rituximab.